12:00 AM
Feb 19, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kallikrein-related peptidase 5 (KLK5); KLK7; KLK14; suppression of tumorigenicity 14 (ST14; matriptase)


INDICATION: Dermatology

In vitro and mouse studies have identified coumarin-3-carboxylate-based protease inhibitors that could help treat skin diseases such as Netherton syndrome, which is characterized by high levels of Kallikrein-related protease activity in the...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >